ClinicalTrials.gg
RecruitingNCT06116721Updated Feb 28, 2024

Evaluation of APOL1 Gene Variants in Kidney Donors and Their Impact on Long-term Renal Function in Donors and Recipients

An observational study in Kidney Diseases and Transplant Failure, sponsored by Hospital do Rim e Hipertensão. Recruiting at 1 site in Brazil. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Hospital do Rim e Hipertensão · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,450
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Kidney Diseases with a site in Brazil — 5 open to participants now, 11 under way, 8 of them phase 3. Kidney Diseases · Brazil.

Started
2023
with 4 others
Observational
6 of 30
2 open now
Primary completion
2024-10
later than 1 of 10 live
Registered
25th of 30
by date

Among the 30 studies in Kidney Diseases with a site in Brazil, this one is one of 5 that started in 2023, is one of 6 observational ones, reaches primary completion later than 1 of the 10 other live ones, and was the 25th registered.

Kidney Diseases

970 studies on the registry are indexed under Kidney Diseases; 185 are open to participants now.

Browse Kidney Diseases studies →

Open to participants now

5 of the 30 studies in Kidney Diseases with a site in Brazil are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 131 Kidney Diseases studies recruiting now, 77 (59%) set no upper age limit and 34 (26%) stop at 75 or younger; 27 take children under 18; 22 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Kidney Diseases with a site in Brazil, or all of them as a file.
02

Study summary

Evaluation of the frequency of APOL1 gene variants in kidney donors and the impact of these variants on the long-term renal function of kidney transplant donors and recipients.

Read the detailed description

Introduction: Chronic kidney disease (CKD) is a worldwide public health problem and kidney transplantation, when indicated, is the treatment of choice for CKD. Kidney transplant survival at the end of the first year is greater than 95%, however, there has not been a corresponding improvement in long-term kidney graft survival outcomes. Factors such as acute or chronic rejection, bacterial or viral infections, de novo or recurrent glomerulopathies are associated with worsening kidney function in the long term. Genetic variants of the Apolipoprotein L1 (APOL1) gene present in individuals with African ancestry (AF) may also interfere with transplant results. In the general population, individuals with SCA have a higher risk of CKD and one of the most accepted hypotheses is that the APOL1 gene is associated with CKD. Genetic variants (G1 and G2) are exclusive to individuals with SCA and confer a higher risk of CKD. In the transplant population, kidneys from deceased donors of African ancestry (AF) with genetic variants of the APOL1 gene have worse renal graft survival. Recipients with the genetic variants, regardless of donor genotype, are at increased risk of rejection and graft loss by immune-mediated mechanisms that damage the kidney through activation of T and NK cells. In Brazil, more than 5000 transplants are performed per year and it is one of the countries outside Africa with the highest number of Afro-descendants, a high rate of miscegenation and a high prevalence of African ancestry. Despite this, there are no studies on the frequency of APOL1 gene variants in this population, as well as their impact on the clinical evolution of kidney transplantation. General objective: To evaluate the association between APOL1 gene risk variants and long-term renal function in living donors and their respective recipients. Specific objectives: i - To measure the prevalence of APOL1 gene variants in the population of living kidney donors; ii - Evaluate the impact of the presence of APOL1 gene risk variants in living kidney donors, on renal graft survival in their respective recipients; iii- To verify the impact of the presence of risk variants of the APOL1 gene on the long-term renal function of living kidney donors after nephrectomy for donation. Methodology: Evaluation of recipients: longitudinal, observational, retrospective cohort study. Adult kidney transplant recipients from a living donor will be included, who have undergone the transplant at the Hospital do Rim in the period between January 1, 2008 and March 31, 2015, and who remained alive and with a functioning graft one year after the transplant. . The observation period will be until March 2020 (five years). The following will be excluded: recipients who have previously undergone transplantation of other organs and recipients who were transferred for follow-up in other centers before 12 months of follow-up after the transplant was performed. Donor evaluation: cross-sectional cohort study in donors who donated a kidney in the period between January 1, 2008 and March 31, 2015. The prevalence of APOL1 gene variants in this population will be determined and clinical information will be evaluated of the donors, from the date of the nephrectomy until the moment of collection of the exams. In the period covered, 2152 transplants were performed with a living donor. It is estimated that the prevalence of APOL1 gene variants is between 8 and 13%, including populations with chronic kidney disease and who underwent kidney transplantation. To calculate the sample number, it will be assumed, by hypothesis, to find a difference of 10 ml/min/1.73m2 in the mean Estimated Glomerular Filtration Rate (eGFR) at the end of 5 years between recipients of kidneys from donors who present some risk mutation (recessive model) compared with those who do not have any risk mutation. To prove this average in the eGFR, the minimum number required is 98 individuals in each group. It will be assumed that the minimum frequency of mutations is 8% in the population of interest, to reach 98 individuals in each group, the total number of individuals required to be evaluated for the presence of mutation will be 1225 donors. Considering that there will be a loss of follow-up of 20% of the total number of individuals, the total number of donors required to be invited will be 1,535 patients. By including 1,225 donors, 1,225 recipients will be included, totaling 2,450 individuals. Primary endpoint: eGFR 5 years after transplantation in recipients. Secondary endpoints: eGFR decay rate between 1 and 5 years after kidney transplantation in recipients; Graft loss in up to 5 years of follow-up; Death in recipients within 5 years of follow-up; Acute rejection. Exploratory outcomes: current eGFR in donors.

03

Conditions studied

  • Kidney Diseases
  • Transplant Failure

Browse trials for

Keywords

  • APOL1 gene
  • Kidney transplantation
  • Living donor
  • Kidney function
  • Kidney graft survival
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

1.1.2.For evaluation of living donor kidney transplant recipients It will be a longitudinal, observational, retrospective cohort study. Adult kidney transplant recipients from a living donor will be included, who have performed the transplant at the Hospital do Rim in the period between January 1, 2008 and March 31, 2015, who remained alive and with a functioning graft one year after the transplant. The observation time will be until March 2020, so that all recipients have had the opportunity to complete at least 5 years of follow-up after transplantation.

Eligibility criteria

Inclusion Criteria:

1.1.1.1. Inclusion criteria 1.1.1.2. For recipients:

  1. Living donor kidney transplant recipients, performed at Hospital do Rim from January 1, 2008 to March 31, 2015;
  2. Recipients Who have reached one year after the transplant, with a functioning renal graft;
  3. Recipients whose donors were located agreed to participate in the research, signed the form (TCLE) and submitted to the collection of exams.

For donors:

  1. Living kidney donors whose donation was made at the Hospital do Rim in the period between January 2008 and December 2015;
  2. That they are alive at the time the study begins;
  3. Who have signed the TCLE.

Exclusion Criteria:

  • For recipients:

    1. Recipients who have undergone the transplant under the age of 18 years;
    2. Recipients who have previously undergone transplantation of other organs; 1.1.3.3. For donors: Donors Who withdraw the informed consent form at any stage of the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,450 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. For evaluation of living donor kidney transplant recipients

    It will be a longitudinal, observational, retrospective cohort study. Adult kidney transplant recipients from a living donor will be included, who have performed the transplant at the Hospital do Rim in the period between January 1, 2008 and March 31, 2015, who remained alive and with a functioning graft one year after the transplant. The observation time will be until March 2020, so that all recipients have had the opportunity to complete at least 5 years of follow-up after transplantation

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Oct 2024, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2023
First posted
Nov 3, 2023
StartActual
Oct 15, 2023
Primary completionEst.
Oct 31, 2024
CompletionEst.
Nov 30, 2025
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06116721
Lead sponsor
Hospital do Rim e Hipertensão
Responsible party
Helio Tedesco Silva Junior (Principal Investigator, Hospital do Rim e Hipertensão) — Principal investigator
First posted
Nov 3, 2023
Start date
Oct 15, 2023
Primary completion
Oct 31, 2024 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Feb 28, 2024

Study contacts

Melissa Gaspar Tavares
study director · Medical Physician
Helio Tedesco Silva Junior
principal investigator · Doctor of Renal Transplant Unit
Mônica Rika Nakamura
study chair · Study coordinator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion